2022
DOI: 10.1097/tp.0000000000003822
View full text
|
Sign up to set email alerts
|

Abstract: Background. Highly sensitized (HS) anti-HLA patients awaiting kidney transplantation benefit from specific allocation programs. Serological monitoring at 3-mo intervals is recommended to prevent unexpected positive crossmatch (XM), but this strategy is not evidence-based. Therefore, we assessed its relevance when using single-antigen flow bead (SAFB) and screening flow bead (SFB) assays. Methods. We included 166 HS patients awaiting a transplant and assessed their SAFB profile during the year preceding their i… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles